Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
December 01 2023 - 8:00AM
Edgar (US Regulatory)
FORM
6-K
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
dated
December 01, 2023
Commission
File Number 0-51504
GENETIC
TECHNOLOGIES LIMITED
(Exact
Name as Specified in its Charter)
N/A
(Translation
of Registrant’s Name)
60-66
Hanover Street
Fitzroy
Victoria
3065 Australia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
☐ No ☒
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
December 01, 2023
|
GENETIC TECHNOLOGIES LIMITED |
|
|
|
By: |
/s/
Tony Di Pietro |
|
Name: |
Tony Di Pietro |
|
Title: |
Company Secretary |
EXHIBIT
INDEX
Exhibit 99.1
Change
to Share Consolidation Timetable
Melbourne,
Australia, 1 December 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global
leader in guideline-driven genomics-based testing in health, wellness and serious diseases, wishes to advise shareholders that there
has been a change to the timetable for the implementation of the shareholder approved 100:1 share consolidation. The change has been
made to align the consolidation with the required changes to the NASDAQ ADS ratio as a result of the share consolidation. The updated
timetable is provided below:
Key event |
|
Updated Timetable
|
Notification to ASX that Consolidation
is approved |
|
22 November 2023 |
|
|
|
Last day for trading in pre-consolidated
securities |
|
8 December 2023 |
|
|
|
Trading in consolidated securities
on a deferred settlement basis commences |
|
11 December 2023 |
|
|
|
Record Date - Last day to register
transfers on a pre-consolidation basis |
|
12 December 2023 |
|
|
|
First day for Company to update
register and send new holding statements to security holders reflecting the change in the number of securities held |
|
13 December 2023 |
|
|
|
Completion of despatch of new
holding statements. Deferred settlement trading ends |
|
19 December 2023 |
|
|
|
Normal trading starts |
|
20 December 2023 |
Authorised
for release by the Board of Genetic Technologies Limited
-END-
Enquiries
Investor
Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: Adrian.mulcahy@automicgroup.com.au
About
Genetic Technologies Limited
Genetic
Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests
in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment
tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform
that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and
individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues
to develop risk assessment products. For more information, please visit www.genetype.com
Forward
Looking Statements
This
announcement may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other
things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made
or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as “believe,” “expect,” “intend,” “plan,” “may,” “should”
or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not
limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made
by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause
the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the
ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities
values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any
obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by law.
Genetic Technologies (PK) (USOTC:GNTLF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Genetic Technologies (PK) (USOTC:GNTLF)
Historical Stock Chart
From Oct 2023 to Oct 2024